Patent classifications
Y10S977/926
UPCONVERSION NANOPARTICLE, HYALURONIC ACID-UPCONVERSION NANOPARTICLE CONJUGATE, AND A PRODUCTION METHOD THEREOF USING A CALCULATION FROM FIRST PRINCIPLES
An upconversion nanoparticle includes at least one host selected from LiYF.sub.4, NaY, NaYF.sub.4, NaGdF.sub.4, and CaF.sub.3, at least one sensitizer selected from Sm.sup.3+, Nd.sup.3+, Dy.sup.3+, Ho.sup.3+, and Yb.sup.3+ doped in the at least one host, and at least one activator selected from Er.sup.3+, Ho.sup.3+, Tm.sup.3+, and Eu.sup.3+ doped in the at least one host. The upconversion nanoparticle is designed using a calculation from first principles to absorb light in the near-infrared wavelength range whose stability is ensured. Further, a hyaluronic acid-upconversion nanoparticle conjugate, in which the upconversion nanoparticle as described above is bonded to hyaluronic acid, is provided to be used in various internal sites with a hyaluronic acid receptor, particularly enables targeting, and increases an internal retention period and biocompatibility thereof.
UPCONVERSION NANOPARTICLE, HYALURONIC ACID-UPCONVERSION NANOPARTICLE CONJUGATE, AND A PRODUCTION METHOD THEREOF USING A CALCULATION FROM FIRST PRINCIPLES
An upconversion nanoparticle includes at least one host selected from LiYF.sub.4, NaY, NaYF.sub.4, NaGdF.sub.4, and CaF.sub.3, at least one sensitizer selected from Sm.sup.3+, Nd.sup.3+, Dy.sup.3+, Ho.sup.3+, and Yb.sup.3+ doped in the at least one host, and at least one activator selected from Er.sup.3+, Ho.sup.3+, Tm.sup.3+, and Eu.sup.3+ doped in the at least one host. The upconversion nanoparticle is designed using a calculation from first principles to absorb light in the near-infrared wavelength range whose stability is ensured. Further, a hyaluronic acid-upconversion nanoparticle conjugate, in which the upconversion nanoparticle as described above is bonded to hyaluronic acid, is provided to be used in various internal sites with a hyaluronic acid receptor, particularly enables targeting, and increases an internal retention period and biocompatibility thereof.
UPCONVERSION NANOPARTICLE, HYALURONIC ACID-UPCONVERSION NANOPARTICLE CONJUGATE, AND A PRODUCTION METHOD THEREOF USING A CALCULATION FROM FIRST PRINCIPLES
An upconversion nanoparticle includes at least one host selected from LiYF.sub.4, NaY, NaYF.sub.4, NaGdF.sub.4, and CaF.sub.3, at least one sensitizer selected from Sm.sup.3+, Nd.sup.3+, Dy.sup.3+, Ho.sup.3+, and Yb.sup.3+ doped in the at least one host, and at least one activator selected from Er.sup.3+, Ho.sup.3+, Tm.sup.3+, and Eu.sup.3+ doped in the at least one host. The upconversion nanoparticle is designed using a calculation from first principles to absorb light in the near-infrared wavelength range whose stability is ensured. Further, a hyaluronic acid-upconversion nanoparticle conjugate, in which the upconversion nanoparticle as described above is bonded to hyaluronic acid, is provided to be used in various internal sites with a hyaluronic acid receptor, particularly enables targeting, and increases an internal retention period and biocompatibility thereof.
POLYMERIZABLE QUANTUM DOT NANOPARTICLES AND THEIR USE AS THERAPEUTIC, ABLATION AND TATTOOING AGENTS
The present disclosure relates to quantum dot nanoparticles conjugated to ligands, and in particular quantum dot nanoparticles wherein each nanoparticle is conjugated to a polymerizable ligand. The present disclosure also relates to methods of making such conjugated quantum dot nanoparticles, and the use of such conjugated quantum dot nanoparticles as therapeutic agents, ablation agents and tattooing agents.
Pulmonary delivery particles comprising an active agent
A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 m. The water insoluble active agent can be a fungicide, antibiotic, budesonide. A method of making the medicament comprises forming a liquid feedstock, and forming a feedstock suspension by suspending in the liquid feedstock, the active agent and an excipient capable of forming a structural matrix, such as a phospholipid. The feedstock suspension is spray dried to produce the particulates.